Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen and Wyeth’s Enbrel gets new arthritis OK
In addition, the FDA has approved an update to the Enbrel (etanercept) label to include new radiographic data demonstrating that Enbrel continued to inhibit the progression of joint
In addition, the FDA has approved an update to the Enbrel (etanercept) label to include new radiographic data demonstrating that Enbrel continued to inhibit the progression of joint
Epratuzumab has been designated by the FDA as a fast track product for the potential treatment of patients with moderate and severe systemic lupus erythematosus (SLE), known as
The approval, for lamivudine tablets 150mg, is Ranbaxy’s first tentative approval under the expedited review process of the US President’s emergency plan for AIDS relief (PEPFAR) program. In
131I-TM-601 is a radiopharmaceutical containing a synthetic version of chlorotoxin, a substance derived from scorpion venom. Chlorotoxin, or TM-601, specifically seeks out and binds to a receptor expressed
The approval means Glumetza will be the first once-daily, extended-release formulation of metformin on the Canadian market. Biovail Pharmaceuticals Canada (BPC), the company’s sales and marketing division, will
This new approach to inhibiting blood vessel growth, or angiogenesis, delivers intraceptors that sequester VEGF (vascular endothelial growth factor), a protein needed to make blood vessels. In a
ITI is developing novel drugs for the treatment of schizophrenia, depression, Parkinson’s and Alzheimer’s disease and other disorders of the central nervous system (CNS). Under the terms of
The objective of the collaboration is to rapidly generate novel biocatalysts for use in manufacturing of Pfizer’s products, improving Pfizer’s R&D productivity while reducing the environmental footprint and
The EMEA orphan drug designation for Proxinium, Viventia’s lead product candidate, follows the FDA’s decision to confer orphan status upon the drug for this indication in January. Proxinium
The trial will evaluate the efficacy and safety of Albuferon (albumin-interferon alpha) in combination with ribavirin in patients with chronic hepatitis C virus (HCV) genotype 1 who are